Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00033488
Status:
COMPLETED
Last Update Posted:
2013-12-18
First Post:
2002-04-09
Brief Title:
Screening Women at High Genetic Risk for Ovarian Cancer
Sponsor:
University College London Hospitals
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
The UK Familial Ovarian Cancer Screening Study
Status:
COMPLETED
Status Verified Date:
2007-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Screening tests may help doctors detect cancer cells early and plan more effective treatment for ovarian cancer
PURPOSE Screening trial to determine the best procedure to detect ovarian cancer in women who have a high genetic risk for developing ovarian cancer
PURPOSE Screening trial to determine the best procedure to detect ovarian cancer in women who have a high genetic risk for developing ovarian cancer
Detailed Description:
OBJECTIVES
Determine an optimal screening procedure for ovarian cancer in terms of the most appropriate screening test criteria for interpretation of results and screening intervals in women at high genetic risk for developing ovarian cancer
Determine the physical morbidity and the resource implications associated with ovarian cancer screening in these women
Assess the feasibility of screening this high-risk population in terms of compliance rates
OUTLINE Patients undergo transvaginal ultrasonography of the ovaries scheduled for the early follicular phase day 3-6 of the menstrual cycle and CA 125 measurement annually Blood samples are collected every 4 months for analysis of CA 125 levels and novel markers
Peer Reviewed and Funded or Endorsed by Cancer Research UK
PROJECTED ACCRUAL A total of 5000 patients will be accrued for this study
Determine an optimal screening procedure for ovarian cancer in terms of the most appropriate screening test criteria for interpretation of results and screening intervals in women at high genetic risk for developing ovarian cancer
Determine the physical morbidity and the resource implications associated with ovarian cancer screening in these women
Assess the feasibility of screening this high-risk population in terms of compliance rates
OUTLINE Patients undergo transvaginal ultrasonography of the ovaries scheduled for the early follicular phase day 3-6 of the menstrual cycle and CA 125 measurement annually Blood samples are collected every 4 months for analysis of CA 125 levels and novel markers
Peer Reviewed and Funded or Endorsed by Cancer Research UK
PROJECTED ACCRUAL A total of 5000 patients will be accrued for this study
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EU-20044 | None | None | None |
| UKFOCSS | None | None | None |
| CRCA-FOCS | None | None | None |